Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Tesamorelin

Plain-language summaryIntrigue 70 / 100

Tesamorelin, sold as Egrifta, is a stabilized GHRH analog FDA-approved for HIV-associated visceral fat accumulation. It produces growth hormone release while preserving the natural pulsatile pattern. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

57/100

FDA-approved GHRH analog with proven visceral fat reduction and an emerging cognitive research angle worth watching

Look, tesamorelin occupies a genuinely interesting position in the GHRH analog space, and that position is mostly defined by what it has that its competitors dont: a real FDA approval backed by actual phase 3 data. Egrifta got its 2010 nod for HIV-associated lipodystrophy, and that approval is anchored in legitimate multicenter RCTs, not the kind of single-lab preclinical story you see from most peptides in this category. For visceral adipose tissue reduction in patients on antiretroviral therapy, it works, and we have the data to say so with confidence.

The structural story is worth understanding. Native GHRH has a plasma half-life in the 7-10 minute range; sermorelin gets you to roughly 11-12 minutes. Tesamorelin’s trans-3-hexenoic acid conjugation at the N-terminus pushes that to around 26 minutes, and more importantly, it preserves the natural pulsatility of GH release. Thats not a trivial distinction. Exogenous GH replacement suppresses endogenous axis function; tesamorelin stimulates it. Mechanistically that’s the cleaner approach, and researchers interested in GH axis physiology have a real reason to reach for it as a probe compound rather than just injecting GH directly. The downstream IGF-1 signal is physiological, not pharmacological, which matters if you’re trying to isolate axis-specific effects.

Where the score gets complicated is novelty. GHRH analogs are a mature class. CJC-1295 with DAC has a dramatically longer half-life if you’re chasing PK. Sermorelin is cheap and accessible. The tesamorelin story really rests on two things: the regulatory anchor, which you can’t dismiss, and an emerging cognitive research thread that we think is the most interesting active science around this compound right now. Multiple investigator groups have looked at tesamorelin in the context of HIV-associated neurocognitive disorder, with a modest but real signal appearing across several small trials. Whether the effect is GH-mediated, IGF-1-mediated, or something more indirect through neuroinflammatory or metabolic pathways is still being worked out, and that ambiguity is actually what makes it worth watching for any program focused on the neuroendocrine-cognition intersection.

Honestly, for a bench scientist the most defensible use case is as a validated GHRH-axis tool with a real human pharmacokinetic and pharmacodynamic dataset behind it, which is more than most peptides in this class can claim. Sourcing is cleaner than average given approved-drug status and peptide-synthesis availability. We’d put this in the serious-but-not-urgent category: real signal, real data, mechanism that’s established rather than exciting. The cognitive angle could shift the assessment if the next round of trials holds up, but right now it reads as confirmatory work on a known platform rather than something at the frontier.

Novelty

40

Mechanism promise

45

In-category differentiation

62

Evidence quality

72

Translational signal

72

Research bench value

55

Rationale Tesamorelin’s trans-3-hexenoic acid modification and its FDA approval in HIV lipodystrophy give it unusually strong evidence and translational scores for a peptide, but the mechanism is single-receptor agonism in a mature class and novelty is correspondingly modest. The HIV-associated neurocognitive disorder research thread is the most scientifically interesting active direction and keeps it from scoring lower.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Stabilized GHRH analog

A trans-3-hexenoic acid stabilized GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy.

Abstract

Tesamorelin (Egrifta; CAS 901758-09-6; molecular weight 5135.79) is a stabilized analog of human GHRH developed by Theratechnologies (Canada) and approved by the FDA in 2010 for HIV-associated lipodystrophy. The structural modification is the addition of a trans-3-hexenoic acid group at the N-terminus, which substantially extends plasma half-life relative to native GHRH or sermorelin. The compound stimulates physiological GH release with restored visceral adipose tissue reduction in HIV patients on antiretroviral therapy. Pharmacokinetics: plasma half-life approximately 26 minutes (versus 11 to 12 minutes for sermorelin); subcutaneous administration. Approved dose is 2 mg subcutaneously once daily.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-080Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Rapamycin (Sirolimus)

Plain-language summaryIntrigue 90 / 100

Rapamycin (sirolimus), sold as Rapamune, is a bacterial natural product originally used as an immunosuppressant after organ transplant. It inhibits the mTOR pathway, a master regulator of cell growth and aging. It is the most studied longevity intervention; Mikhail Blagosklonny’s hypothesis that intermittent rapamycin slows aging has driven extensive research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel frontier

81/100

The reference mTOR probe with the strongest pharmacological longevity evidence base in existence

Rapamycin is one of those compounds where the research arc keeps bending. Isolated in 1972 from an Easter Island soil sample, it spent decades as a transplant drug before the field realized it might be doing something far more interesting. The ITP data published in 2009 changed the conversation: genetically heterogeneous mice started on late treatment showed genuine lifespan extension, reproducible across three independent sites. That replication matters. Single-lab longevity claims are everywhere; multi-site ITP confirmation is rare, and rapamycin has it.

The mechanism is mTORC1 inhibition through FKBP12 binding, and what makes this compelling isn’t just the immunosuppression angle. mTOR sits at a genuine convergence point: nutrient sensing, autophagy flux, cellular senescence accumulation, ribosomal biogenesis, and downstream effects on age-related inflammation. When you inhibit mTORC1 appropriately, you’re essentially pulling one lever and hitting multiple aging hallmarks simultaneously. Thats the kind of mechanistic elegance that serious geroscience investigators care about.

What we like here is the bench utility. Rapamycin is the reference probe for mTOR biology. If you’re studying nutrient sensing, autophagy, senescence, cancer metabolism, or aging at the cellular level, you need rapamycin in your toolkit. There isn’t a cleaner or better-validated way to inhibit mTORC1. The rapalogs (everolimus, temsirolimus) exist but they’re downstream of rapamycin’s place in the literature and are mostly disease-specific derivatives. For research purposes, this is the compound.

The evidence base is unusually strong for a compound in this space. FDA approval for renal transplant means substantial human PK/PD data. The ITP multi-site replication puts the lifespan extension data above essentially anything else in the pharmacological longevity field. Human longevity-focused trials are underway, including the PEARL study and other geroscience protocols using intermittent dosing schedules to mitigate the immunosuppressive effects that complicate chronic daily administration.

Honestly, the main concern isn’t mechanism or evidence, it’s the mTORC2 question. Chronic dosing starts to affect mTORC2 in ways that can blunt some of the intended benefits, and there’s real debate about optimal dosing intervals in the longevity context. The intermittent dosing hypothesis is sensible mechanistically but not definitively proven in humans yet. That uncertainty is a legitimate open question, not a reason to deprioritize the compound. For investigators working on longevity biology, mTOR pathway signaling, senescence research, or metabolic aging, rapamycin isnt optional. It defines the field.

Novelty

62

Mechanism promise

85

In-category differentiation

88

Evidence quality

85

Translational signal

82

Research bench value

90

Rationale Rapamycin holds an unusual position: FDA-approved with massive clinical PK/PD data, AND the most replicated pharmacological longevity intervention on record via ITP multi-site confirmation. Novelty is constrained by the compound’s 50-year age, but its role as the irreplaceable mTOR probe, its central mechanism in aging biology, and an active clinical longevity research program justify high scores across mechanism, differentiation, evidence, and bench value.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

mTOR inhibitor / immunosuppressant

A bacterial macrolide isolated from Streptomyces hygroscopicus, FDA-approved as an immunosuppressant and increasingly investigated for longevity applications through mTOR inhibition.

Abstract

Rapamycin (Sirolimus, Rapamune; CAS 53123-88-9; molecular formula C51H79NO13; molecular weight 914.17) is a macrolide compound isolated in 1972 from Streptomyces hygroscopicus from Easter Island (Rapa Nui, providing the name). The compound was approved by the FDA in 1999 as an immunosuppressant for renal transplantation. Mechanism is selective inhibition of mTORC1 (mammalian target of rapamycin complex 1) through binding to FKBP12 and forming a complex that allosterically inhibits mTOR kinase activity. Beyond immunosuppression, rapamycin extends lifespan in multiple model organisms (yeast, worms, flies, mice) when administered late in life, making it the most extensively documented pharmacological intervention for lifespan extension. The Interventions Testing Program (ITP) at NIA showed reproducible lifespan extension in genetically heterogeneous mice. Mechanisms of lifespan extension include reduced cellular senescence, improved autophagy, attenuation of age-related inflammation, and reduced age-related cancer incidence. The compound is increasingly used off-label for longevity applications by physicians and patients pursuing geroscience interventions; intermittent dosing schedules (5 to 10 mg weekly or monthly) are used to reduce immunosuppressive effects. Pharmacokinetics: plasma half-life 60 to 70 hours; high oral bioavailability; CYP3A4 metabolism.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-095Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Reishi (Ganoderma lucidum)

Plain-language summaryIntrigue 50 / 100

Reishi (Ganoderma lucidum) is a medicinal mushroom traditionally used in East Asia for longevity, immunity, and sleep. Triterpenes and polysaccharides drive the immunomodulatory effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

27/100

Well-characterized OTC mushroom with modest clinical signal and limited research differentiation

Look, reishi has a real chemistry story. Ganoderic acids A through Z are genuine triterpenoids with measurable bioactivity, and the beta-glucan component drives TLR2/TLR4 agonism that immunologists care about as a mechanism class. So we’re not dismissing it as pure folk medicine. But the question the rubric asks is whether a serious bench scientist should prioritize it right now, and the honest answer is: probably not.

The novelty problem is fundamental. Reishi has been in continuous research circulation since at least the 1980s, and the active constituent classes — triterpenes, polysaccharides, ergosterols — are thoroughly mapped. Theres no fresh mechanism emerging here, no recently discovered target, no signal that the field is about to be surprised. Compare that to something like MOTS-c, where the mitochondrial origin and AMPK axis were genuinely new biology just a few years ago. Reishi occupies the opposite end of that spectrum.

Differentiation is the harder problem. If you’re studying beta-glucan immunomodulation, turkey tail (Trametes versicolor, PSK/PSP) has materially stronger RCT evidence, including adjunct use in cancer contexts with reasonable replication. If you want TLR agonism biology, there are cleaner purified tools. If you want adaptogenic physiology, rhodiola and panax ginseng have bigger human literature. Reishi doesn’t clearly lead in any of these lanes, and that matters when you’re choosing what goes into a research program.

What we do find defensible is its evidence quality relative to other adaptogens — the preclinical literature is genuinely multi-lab and reasonably methodical, and there are RCTs, even if the effect sizes tend toward modest and the endpoints tend toward surrogate immunological markers rather than hard outcomes. The translational signal is real but diffuse. Nobody has nailed down what reishi does to a human that nothing else does better or cheaper.

The bench value case exists in narrow contexts: investigators specifically studying Ganoderma triterpenoid chemistry, groups building comparative mushroom panels, or anyone characterizing TLR-activating polysaccharide structure-activity relationships. Outside of those niche programs, it’s hard to argue that including reishi in a research protocol answers a question you couldn’t answer another way. Honestly, it’s the cordyceps situation: the compound category is capped by its OTC status and genericism, and the raw score confirms that cap isn’t even needed to land low.

Novelty

20

Mechanism promise

30

In-category differentiation

22

Evidence quality

35

Translational signal

28

Research bench value

28

Rationale Raw score lands below the common OTC food/herb cap of 35, so the cap doesn’t bind — the compound just isn’t interesting enough to score higher on its own merits. Beta-glucan TLR agonism and ganoderic acid chemistry are real but neither is novel nor uniquely attributable to reishi vs. competing mushrooms with stronger evidence.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Medicinal mushroom

A medicinal mushroom with traditional use in immune support and longevity, characterized by triterpenoids (ganoderic acids) and beta-glucan polysaccharides.

Abstract

Reishi (Ganoderma lucidum, Lingzhi) is a medicinal mushroom with millennia of traditional use in Chinese medicine for immune support, longevity, and cardiovascular function. Active constituents include triterpenoids (ganoderic acids A through Z), beta-glucan polysaccharides, and ergosterols. Mechanism is multimodal including immunomodulation through TLR agonism (beta-glucans), modest anticancer effects (triterpenoids), and modulation of platelet aggregation. The clinical evidence base in randomized trials is modest; the compound is more of a general adaptogen than a targeted therapeutic. Doses are typically 1 to 3 grams per day of mushroom extract.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-112Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Thymogen

Plain-language summaryIntrigue 45 / 100

Thymogen is a synthetic dipeptide (Glu-Trp) immunomodulator developed in Russia, derived from research on thymic hormones. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

37/100

Russian-approved thymic dipeptide with real but geographically isolated evidence and conventional immunomodulatory mechanism

Thymogen is the synthetic Glu-Trp dipeptide, pulled from bovine thymus extract by the fractionation work that produced the broader thymalin literature. It’s a legitimately interesting research object in a narrow sense: two amino acids, modest immunomodulatory activity, and a regulatory approval history that puts it above the purely speculative tier. But we have to be honest about what we’re dealing with here.

The mechanism story is straightforward and not especially exciting. Thymic peptides generally modulate T-cell maturation and cytokine output, and Thymogen does this at the dipeptide level. Thats useful to know, but the actual pharmacology is conventional thymic biology, not a novel axis. Compare it to thymosin alpha-1, which has a much richer literature, phase 2/3 trial experience in HIV and hepatitis, and real credibility in the immunostimulant space. Against that competition, Thymogen is clearly secondary.

The evidence situation is the main drag. The literature is almost entirely Russian-language, produced within a small set of institutes associated with the Khavinson/bioregulator tradition. Regulatory approval in Russia and several former Soviet states means there’s real clinical use, but the methodology behind those approvals is opaque by Western standards. There’s essentially no independent multi-lab replication, no phase 2/3 data by EMA or FDA standards, and no published systematic reviews we can assess with confidence.

What we like: the synthetic dipeptide approach is clean. If someone wants to study minimal thymic signaling molecules as probes for T-cell maturation pathways, Thymogen is small, well-defined, and accessible. That’s genuinely more useful than starting with a crude thymus extract. And the intranasal route is interesting from a delivery standpoint if you’re studying mucosal immune signaling in rodent models.

What we don’t like: the mechanism doesn’t differentiate it from better-studied alternatives in the thymic peptide space. Thymosin alpha-1 exists. Thymopentin exists. The Glu-Trp story hasn’t generated the kind of mechanism-deep papers that would justify prioritizing this over those options for a serious research program. The approved-in-Russia status is worth noting but doesn’t substitute for replication outside that regulatory tradition.

For investigators specifically building out a thymic peptide panel or studying minimal bioactive dipeptides as a structural class, Thymogen has real bench value. For most Western research contexts, the evidence base doesn’t justify leading with it over better-characterized alternatives.

Novelty

48

Mechanism promise

33

In-category differentiation

28

Evidence quality

37

Translational signal

42

Research bench value

30

Rationale Thymogen has regulatory approval within Russia and the FSU but the evidence base is single-consortium and lacks Western replication; mechanism is conventional thymic immunobiology with no novel axis, and thymosin alpha-1 clearly dominates the therapeutic space it occupies.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic dipeptide immunomodulator

A synthetic dipeptide (Glu-Trp) developed in Russia as an immunomodulator for infectious and post-surgical immune support.

Abstract

Thymogen is the dipeptide L-glutamyl-L-tryptophan, developed in Russia at the Institute of Bioregulation and Gerontology. The compound was identified through fractionation of thymalin (bovine thymus extract) as one of the active components. Thymogen is approved in Russia and several former Soviet states for infectious diseases, post-surgical immune support, and hematopoietic recovery after chemotherapy. Mechanism includes modest T-cell maturation effects and cytokine modulation. Administered intranasally or intramuscularly. Doses are 100 micrograms per day in 3 to 10 day courses.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-129Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
L-Tyrosine

Plain-language summaryIntrigue 55 / 100

L-tyrosine is the amino acid precursor for catecholamine neurotransmitters (dopamine, norepinephrine, epinephrine). Supplementation may help during stress, sleep deprivation, or cold exposure when catecholamines deplete faster than they are synthesized. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic amino acid

25/100

Well-understood catecholamine precursor with context-dependent stress signal and minimal research frontier value

Look, L-Tyrosine is exactly what it says it is: a dietary amino acid that sits at the top of the catecholamine biosynthesis ladder. Tyrosine hydroxylase converts it to L-DOPA, and from there you get dopamine, norepinephrine, epinephrine. That pathway has been understood since the 1960s. Theres nothing mechanistically new here, and we dont think theres much point pretending otherwise.

The stress-depletion framing is the only angle that generates any genuine research interest. The core hypothesis is that under conditions of high catecholamine demand, specifically sleep deprivation, cold exposure, sustained vigilance tasks, tyrosine hydroxylase may become substrate-limited. If so, supplementation could in principle restore catecholamine synthesis capacity faster than dietary intake alone would. That logic is physiologically sound. The problem is that the effect in practice is modest, highly context-dependent, and most prominent in subjects who are already meaningfully stressed or depleted. In rested, replete humans, the signal essentially disappears. That’s a real finding, but it’s not a surprising one and it’s not a frontier one.

On the human evidence side, we actually have multiple well-run studies here, with the Deijen group and others replicating cognitive task performance effects under acute stress. N-back performance, tracking task accuracy, subjective alertness under sleep loss, these endpoints show measurable but small effect sizes when tyrosine is given acutely before or during a stressor. Thats a cleaner dataset than many compounds in our library. The issue isnt evidence quality. Its that the question these studies answer is not a question that serious bench investigators are actively racing to resolve in 2026.

Differentiation is poor. NALT (N-acetyl-L-tyrosine) is frequently preferred by formulators for claimed bioavailability reasons, though the evidence there is also murky. Mucuna pruriens delivers L-DOPA directly and bypasses the tyrosine hydroxylase rate-limit entirely if you actually want to push catecholamine tone. If someone is studying catecholamine biology at the bench, they have better tools than oral tyrosine. The compound has almost no probe value for a research program that isn’t specifically studying precursor loading dynamics.

Honestly, the compound belongs in a formulators pantry, not on a frontier research shortlist. What we like: the evidence is real, the mechanism is clean, the sourcing is trivial. What we dont like: none of those things make it interesting as a research target in 2026. The novelty axis in particular is terminal here. This is a 60-year-old molecule with a settled mechanism and a modest, well-characterized effect. If your program is specifically about catecholamine depletion models in human subjects, tyrosine has a role. Otherwise, its background noise.

Novelty

12

Mechanism promise

20

In-category differentiation

15

Evidence quality

48

Translational signal

42

Research bench value

25

Rationale L-Tyrosine is a foundational amino acid with textbook-level mechanism; raw scores land well below the basic-aa cap of 32. Evidence quality and translational signal are real but modest and context-specific, not enough to lift overall above 25.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Catecholamine precursor amino acid

An aromatic amino acid precursor of L-DOPA, dopamine, norepinephrine, and epinephrine; supplemented for stress-related catecholamine support.

Abstract

L-Tyrosine (CAS 60-18-4; molecular formula C9H11NO3; molecular weight 181.19) is an aromatic amino acid precursor in the catecholamine biosynthesis pathway: tyrosine → L-DOPA (via tyrosine hydroxylase) → dopamine → norepinephrine → epinephrine. Supplementation has been studied for cognitive performance under stress conditions where catecholamine demand is high (sleep deprivation, cold exposure, sustained vigilance tasks); modest improvements in cognitive endpoint measures have been reported. Effects on resting cognitive performance are minimal. Tyrosine hydroxylase is the rate-limiting enzyme; supplementation can increase substrate availability when the enzyme is operating below saturation. Doses are typically 500 mg to 2 grams per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-145Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Brexanolone

Plain-language summaryIntrigue 78 / 100

Brexanolone, sold as Zulresso, is recombinant allopregnanolone administered as a 60-hour IV infusion for postpartum depression. The first FDA-approved postpartum depression specific treatment (2019). Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

51/100

FDA-approved neurosteroid for PPD with real evidence but limited bench access and zuranolone superseding it

Look, the clinical story here is genuinely compelling. Brexanolone was the first FDA-approved neuroactive steroid targeting postpartum depression, and the phase 3 data from Sage’s pivotal trials (BRX-300 and BRX-301) showed rapid symptom resolution within 24-48 hours of infusion start. For a field accustomed to antidepressants taking weeks, thats actually striking. The mechanism is real: brexanolone acts as a positive allosteric modulator at GABA-A receptors, with particular affinity for extrasynaptic delta-subunit-containing receptors that benzodiazepines largely miss.

That delta-subunit selectivity is the interesting part. Classic benzo pharmacology hits synaptic gamma2-containing receptors; the extrasynaptic pool is tonically active and responds to neurosteroids like allopregnanolone specifically. The working hypothesis behind the PPD indication is that parturition triggers a rapid collapse of neurosteroid tone, and that reconstituting it via prolonged IV infusion can reset the system quickly. It’s a coherent, testable model, and the clinical data supports it in at least this one population.

The problem for research utility is everything around the pharmacology. The compound itself is endogenous allopregnanolone; brexanolone is the formulation, not a new chemical entity. Achieving sustained plasma concentrations required a 60-hour inpatient infusion with continuous monitoring, which is exactly why the FDA required a REMS. That REMS means restricted distribution, certified inpatient settings only, and a monitoring protocol that would be deeply inconvenient for most bench programs. We’re not rating clinical accessibility, but bench value is part of the score, and a compound you cant source without navigating REMS bureaucracy has real limits as a probe.

Honestly, the arrival of zuranolone changes the picture considerably. Zuranolone is the same neurosteroid pharmacology in an oral formulation with a much cleaner access profile for investigators interested in the delta-subunit story. If you want to study extrasynaptic GABA-A modulation by neuroactive steroids in 2026, zuranolone is the practical choice. Brexanolone’s value proposition has narrowed to historical reference standard and approved clinical agent rather than active research tool.

What we like: evidence quality is high, the mechanism is genuinely more nuanced than generic GABAergic pharmacology, and the PPD indication opened a real research window on peripartum neurosteroid dynamics that remains active. What we dont like: the IV REMS delivery model makes it nearly inaccessible as a bench compound, the chemical novelty is essentially zero since this is an endogenous molecule, and zuranolone largely supersedes it for the research questions that matter going forward. The clinical chapter here is closed and well-written; the research chapter probably isn’t brexanolone’s to write.

Novelty

40

Mechanism promise

55

In-category differentiation

40

Evidence quality

72

Translational signal

70

Research bench value

28

Rationale Brexanolone scores well on evidence and translational signal (FDA-approved, phase 3 RCTs, rapid PPD symptom resolution) but is penalized heavily on bench value due to IV-only REMS delivery, and on novelty and differentiation because the chemical entity is endogenous allopregnanolone and zuranolone now covers the same pharmacology orally.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic allopregnanolone (IV)

Synthetic allopregnanolone formulated for IV administration, FDA-approved as Zulresso for postpartum depression.

Abstract

Brexanolone (Zulresso; SAGE-547; CAS 516-54-1, same as endogenous allopregnanolone) is a synthetic preparation of allopregnanolone formulated for 60-hour intravenous infusion, developed by Sage Therapeutics and approved by the FDA in 2019 for postpartum depression. The compound is identical in structure to endogenous allopregnanolone; the development innovation was the formulation enabling sustained therapeutic plasma concentrations through prolonged IV infusion. Mechanism is GABA-A receptor positive allosteric modulation. Schedule IV. Restricted distribution program (REMS) due to risk of excessive sedation and loss of consciousness. The closely related zuranolone provides oral dosing with similar pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-161Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Forskolin

Plain-language summaryIntrigue 55 / 100

Forskolin is a diterpene from the Coleus forskohlii plant root. It directly activates adenylyl cyclase, raising intracellular cAMP. Used in research as a cAMP elevator and as a supplement for weight loss (with limited evidence). Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

Mature cAMP-elevating probe with a unique mechanism but weak clinical translation and low novelty

Cap applied Common OTC food/herb — max 35

Look, forskolin has a genuinely interesting mechanism on paper. Direct activation of adenylate cyclase, bypassing G-protein-coupled receptors entirely, means you can elevate intracellular cAMP in essentially any cell type without needing a receptor-level handle. Thats a real pharmacological property. The problem is that “raises cAMP” is also one of the most crowded and least surprising things you can do in a cell biology experiment. Caffeine does it. IBMX does it. Rolipram does it. The question isnt whether you can raise cAMP; its whether you have something meaningful to say once you do.

The clinical story for forskolin is mostly disappointment. The obesity work is the most widely cited, and it’s not good. The Godard et al. 2005 RCT in overweight men showed some body composition signal; a companion trial in women did not replicate the lean mass effect. Glaucoma is the one application where topical ophthalmic formulations have shown real intraocular pressure reduction, but that work belongs to a specific delivery context and formulation space, not to standardized coleus extract as broadly studied. Cardiovascular work from the 1980s and 90s was conducted under IV administration conditions that don’t translate to anything commercially or bench-practically relevant today. We don’t think there is a compelling modern indication sitting here waiting to be unlocked.

The mechanism differentiation is the only thing keeping this compound from scoring lower. You cannot directly activate adenylate cyclase with most available tools, so forskolin genuinely earns its place as a positive control for cAMP-dependent pathway studies in cell culture. That’s real bench value. But it’s not indispensable. Dibutyryl-cAMP analogs, cholera toxin in specific contexts, and phosphodiesterase inhibitors all compete for the same experimental slot. Forskolin is convenient and cheap, not irreplaceable.

What we dont like here is the gap between mechanism plausibility and clinical delivery. The translational arrow points nowhere useful in 2026. Weight loss signal in humans is unimpressive and inconsistent across cohorts and sexes. Cardiovascular effects are pharmacologically interesting in isolated myocardium preparations but haven’t generated anything a modern cardiologist would act on. The glaucoma angle is arguably the strongest and most specific, but it isnt what drives the supplement market’s interest or the research community’s attention to this compound.

Honestly, if you’re building a research program around cAMP signaling, you’d include forskolin as a probe and positive control, not as the headline compound. Compared to what’s happening in dual and triple incretin biology, mitochondrial-derived peptides, and NNMT inhibition, a four-decade-old plant diterpene doesn’t move the needle. There’s nothing wrong with it as a tool. It just doesn’t represent where the interesting science is happening right now, and the supplement-market noise around it obscures rather than sharpens the actual research question.

Novelty

20

Mechanism promise

38

In-category differentiation

42

Evidence quality

36

Translational signal

30

Research bench value

60

Rationale Forskolin’s direct adenylate cyclase activation is mechanistically distinct from receptor-mediated cAMP elevation and earns genuine bench credit as a positive control tool, but the compound is four decades old, its clinical signal across obesity and cardiovascular indications is inconsistent and modest, and the OTC herb cap binds at 35 given its primary commercial identity as a Coleus forskohlii extract supplement.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Coleus forskohlii diterpene

A labdane diterpene from Coleus forskohlii root with adenylate cyclase activation activity, used for cardiovascular and metabolic applications.

Abstract

Forskolin (CAS 66575-29-9; molecular formula C22H34O7; molecular weight 410.50) is a labdane diterpene isolated from the root of Coleus forskohlii (Plectranthus barbatus), a perennial plant native to India. The compound is a direct activator of adenylate cyclase (independent of receptor activation), elevating intracellular cAMP across many cell types. Pharmacology includes positive inotropy (cardiac), vasodilation, lipolysis, and bronchodilation. Forskolin has been studied for hypertension, cardiovascular dysfunction, glaucoma, and obesity (the latter primarily in dietary supplement form). Doses are typically 250 to 500 mg of standardized extract (10 to 20 percent forskolin) per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-177Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Exenatide

Plain-language summaryIntrigue 75 / 100

Exenatide, sold as Byetta and Bydureon, is the original GLP-1 receptor agonist. It is derived from a peptide in Gila monster saliva (exendin-4). The Bydureon formulation is the long-acting once-weekly version. FDA-approved for type 2 diabetes. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

40/100

First-in-class GLP-1 agonist that defined its category but is now clearly outclassed by semaglutide, tirzepatide, and retatrutide

Look, exenatide has a genuinely interesting origin story. A peptide pulled from Gila monster venom that turned out to be a DPP-4-resistant GLP-1 receptor agonist was a meaningful discovery in 2005 when Byetta first hit the market. Exendin-4’s 53% sequence homology with human GLP-1 but its resistance to enzymatic cleavage was a real structural insight, and the Bydureon once-weekly formulation was a legitimate advance in peptide delivery. The compound helped prove that GLP-1 agonism was a viable therapeutic class. Credit where it’s due.

The problem is that two decades of drug development have clearly moved past it. Semaglutide does everything exenatide does but better: superior HbA1c reduction, more weight loss, strong SUSTAIN and SELECT cardiovascular outcomes data, and now an oral formulation. Tirzepatide adds dual GIP/GLP-1 agonism and produces weight loss figures exenatide couldn’t approach. Retatrutide goes further still with triple agonism. On differentiation, exenatide isn’t just one of many similar agents in its class. It’s actively outclassed by its successors. There’s no serious metric where you’d reach for exenatide over semaglutide when designing new research into GLP-1 biology in metabolic disease.

The one area where exenatide retains genuine research interest is neurodegeneration. The EXENATIDE-PD trial (Athauda et al., 2017, Lancet) reported that subcutaneous exenatide produced improvements in motor scores in Parkinson’s disease that persisted after washout, suggesting disease-modifying rather than purely symptomatic effects. A follow-up trial produced a messier result, which is a familiar pattern in small-N Parkinson’s trials. There’s ongoing work examining GLP-1 receptor signaling in dopaminergic neurons, neuroinflammation, and alpha-synuclein pathology, and exenatide is the probe that carries the most clinical data in that niche. Thats real bench utility, even if it’s narrow.

We’d say the EXENATIDE-PD signal is the one thing that keeps exenatide from being a pure historical artifact. But even there, liraglutide is competing for the same mechanistic questions, and if you’re starting a new CNS-focused GLP-1 program today, you’d probably want to characterize what more potent, newer agonists do in the brain before anchoring to exenatide. The evidence quality for the metabolic indication is genuinely solid, an approved drug with multiple RCTs and real pharmacovigilance data, but strong evidence on an old compound that’s been outperformed doesnt make it a compelling research target. A serious investigator today would only reach for exenatide if extending the EXENATIDE-PD line of work specifically, or needing a well-characterized reference GLP-1 agonist in a head-to-head comparison. Narrow use case. Score reflects it.

Novelty

25

Mechanism promise

38

In-category differentiation

22

Evidence quality

65

Translational signal

60

Research bench value

40

Rationale Exenatide scores low on novelty and differentiation because it has been definitively superseded by newer GLP-1 and dual/triple agonists on every primary metric; its only meaningful residual research angle is the EXENATIDE-PD Parkinson’s neuroprotection signal, which provides modest bench utility but does not rescue the overall score.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GLP-1 receptor agonist (exendin-4)

A synthetic version of the Gila monster venom peptide exendin-4, FDA-approved as Byetta (twice daily) and Bydureon (weekly) for T2DM.

Abstract

Exenatide (Byetta, Bydureon; CAS 141758-74-9; molecular weight 4186.57) is a synthetic version of exendin-4, a 39-amino-acid peptide originally isolated from Gila monster (Heloderma suspectum) venom. The compound is a GLP-1 receptor agonist with substantial structural difference from human GLP-1, providing resistance to DPP-4 cleavage. Exenatide was the first GLP-1 receptor agonist approved (Byetta, 2005); the extended-release formulation (Bydureon, 2012) provides once-weekly administration. Approved doses are 5 to 10 micrograms twice daily (Byetta) or 2 mg weekly (Bydureon).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-193Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Desvenlafaxine

Plain-language summaryIntrigue 50 / 100

Desvenlafaxine (Pristiq) is the major active leftover of venlafaxine, repackaged and sold on its own by Wyeth and Pfizer starting in 2008. The therapeutic logic was that giving the metabolite directly bypasses a liver enzyme called CYP2D6, which is genetically variable: some people break venlafaxine down quickly, others slowly, and that variability creates unpredictable blood levels. Skipping the conversion step gives flatter, more uniform pharmacology across patients. Mechanistically it does the same thing as the parent: blocks both the serotonin and norepinephrine pumps, with a slightly more balanced ratio between the two. Approved for major depressive disorder. Most prescribers consider it modestly different from generic venlafaxine, not dramatically so. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

37/100

A pharmacokinetic refinement of venlafaxine with no meaningful mechanistic novelty for bench researchers

Look, desvenlafaxine is the active metabolite of venlafaxine, approved as Pristiq in 2008, and it’s about as far from a frontier research compound as you can get while still being a real drug. The SERT/NET dual inhibition story it tells is exactly the same story venlafaxine has been telling since 1993. The compound exists primarily because of CYP2D6 polymorphism: roughly 7-10% of Caucasians are poor metabolizers who can’t efficiently convert venlafaxine to its active form, so Wyeth/Pfizer developed desvenlafaxine to produce predictable plasma concentrations regardless of phenotype. That is a pharmacokinetic convenience. Its not a mechanistic discovery.

The SERT affinity (Ki approximately 40 nM) and NET affinity (Ki approximately 558 nM) are functionally comparable to the parent compound. Theres a modest argument that the SERT/NET ratio favors more meaningful NET inhibition at lower doses compared to venlafaxine, which could theoretically matter for certain pharmacodynamic designs, but this is a subtle consequence of metabolite kinetics, not a distinct mechanism. The SNRI class has been exhaustively characterized. What would a bench scientist actually learn from a desvenlafaxine experiment that they haven’t already extracted from venlafaxine, duloxetine, or milnacipran?

Here’s the thing: the evidence base is genuinely solid. Multiple phase 3 RCTs supported FDA approval for major depressive disorder, and there’s a real replicated literature on vasomotor symptom management in perimenopausal populations. We’re not disputing that desvenlafaxine works. The clinical profile is well-documented and reproducible across phenotypes. The evidence and translational scores reflect that honestly.

But clinical efficacy is not the point of a research library score. The question is whether a serious investigator should be reaching for desvenlafaxine as a research tool or subject in 2025. Rarely. If you’re running a PK study that needs to control for CYP2D6 variability, it’s a useful reference SNRI with flat steady-state kinetics, and that specific niche is real. Outside that methodological use case, the compound offers nothing venlafaxine doesn’t already offer, and venlafaxine offers nothing newer antidepressants don’t at least match on mechanism interest. The flat dose-response curve above 50 mg is actually a liability for dose-ranging research designs.

We’d reserve this for investigators explicitly studying CYP2D6 pharmacology, drug-drug interaction models, or comparative PK design. Everyone else studying SNRI biology has better, more interesting tools available. The score here is earned by what desvenlafaxine actually is: a metabolite turned product, well-characterized, clinically real, and research-boring.

Novelty

18

Mechanism promise

22

In-category differentiation

22

Evidence quality

78

Translational signal

70

Research bench value

28

Rationale Desvenlafaxine is a marketed SNRI with solid clinical evidence but near-zero novelty; its sole differentiation from venlafaxine is CYP2D6-independent clearance, a clinical convenience rather than a research insight. High evidence and translational scores are heavily outweighed by rock-bottom novelty, mechanism, and differentiation axes.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Active metabolite of venlafaxine (SNRI)

The major active metabolite of venlafaxine; a pure SNRI marketed separately to bypass CYP2D6 polymorphism.

Abstract

Desvenlafaxine (4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol; CAS 93413-62-8; molecular formula C16H25NO2; molecular weight 263.38) is the O-desmethylated active metabolite of venlafaxine, marketed as Pristiq by Wyeth/Pfizer after FDA approval in 2008. The compound is a structurally similar SNRI to venlafaxine with comparable SERT (Ki approximately 40 nM) and NET (Ki approximately 558 nM) affinity but a more balanced ratio than the parent compound, producing meaningful NET inhibition at lower doses. The principal pharmacokinetic advantage is bypass of CYP2D6 metabolism: desvenlafaxine is conjugated and excreted directly without further hepatic transformation, producing flat steady-state concentrations across CYP2D6 phenotypes and minimal drug-drug interaction potential. Plasma half-life is approximately 11 hours; the standard clinical dose is 50 mg daily with a flat dose-response above 50 mg. Discontinuation syndrome is comparable to venlafaxine. Used as a reference SNRI compound when CYP2D6 variability is undesirable.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-208Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Rasagiline

Plain-language summaryIntrigue 66 / 100

Rasagiline (Azilect) is a second-generation MAO-B inhibitor from Teva, approved by the FDA in 2006 for Parkinson disease. It is structurally distinct from selegiline (built around an indane scaffold rather than a phenethylamine) and the key practical advantage is that the body does not break it down into amphetamine derivatives. That eliminates one of the more annoying features of selegiline and makes drug screening cleaner. Like selegiline it binds MAO-B irreversibly, so a single daily dose keeps the enzyme suppressed for weeks. The ADAGIO trial controversially suggested it might also slow disease progression rather than just treat symptoms, although that finding has not been universally accepted. Used as monotherapy in early Parkinson and as an add-on in advanced disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

Mature MAO-B reference standard with solid clinical evidence but limited frontier research appeal

Rasagiline is the second-generation irreversible MAO-B inhibitor that largely displaced selegiline’s role in Parkinson pharmacology by doing one thing better: it doesn’t metabolize to amphetamines. That’s a meaningful difference in practice. No methamphetamine or l-amphetamine metabolites means cleaner drug-screen profiles, no cardiovascular overstimulation at clinical doses, and no tyramine restriction at the approved 1 mg daily dose. Teva’s development team got this right, and the FDA agreed in 2006. The PRESTO, TEMPO, and LARGO trials gave it solid regulatory legs across both monotherapy and levodopa-adjunct settings.

The more interesting research angle isnt the MAO-B inhibition itself, which is textbook at this point, but the propargylamine-mediated neuroprotection signal that sits underneath it. The propargyl group appears to influence Bcl-2 family expression, APP processing, and mitochondrial membrane stability through mechanisms that are partly independent of MAO-B. The ADAGIO delayed-start trial tried to pin this down. At 1 mg, it showed a weak disease-modification signal; at 2 mg, it didn’t, which muddied the interpretation. The FDA reviewed this carefully and declined a neuroprotection label claim, but the biological question isnt fully closed, and several groups have continued probing propargylamine biology in cell and rodent models. Thats where the remaining bench interest lives.

Here’s the thing though: rasagiline isnt on the frontier anymore. Safinamide arrived as a reversible, selective MAO-B inhibitor with an additional sodium-channel and glutamate-release angle that gives it a more interesting pharmacological story for combination PD research. The longevity-oriented MAO-B work has largely migrated toward broader monoamine biology in the context of aging rather than Parkinson’s specifically, and rasagiline doesn’t have the novel positioning to anchor that conversation the way a mitochondrial-targeted peptide or an mTOR-adjacent compound might. Its 14:1 MAO-B selectivity is good; it’s just not surprising anymore.

We think rasagiline earns its place in a research library as a reference standard rather than a frontier target. If your program involves dopamine metabolism, MAO-B selectivity profiling, or the propargylamine neuroprotection hypothesis, it’s a clean, well-sourced, thoroughly characterized tool. The irreversible kinetics are well-documented; the approximately 14-day recovery period is practically useful for experimental design. It’s just not a compound where bench work is likely to surface surprising findings in 2026. The primary questions have been asked, the big trials are done, and the remaining uncertainty around neuroprotection is real but not easily resolved at bench scale. Solid compound. Not an exciting one.

Novelty

22

Mechanism promise

38

In-category differentiation

42

Evidence quality

72

Translational signal

68

Research bench value

52

Rationale Rasagiline scores well on evidence and translational signal as an FDA-approved Phase 3-validated drug, but nearly 20 years of market presence and a fully characterized mechanism drag novelty and differentiation down sharply; safinamide’s reversible inhibition plus glutamate-modulation angle has moved the field forward, leaving rasagiline as a clean reference compound rather than a compelling new research target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective irreversible MAO-B inhibitor (second-generation)

A second-generation propargyl MAO-B inhibitor lacking the amphetamine metabolites of selegiline.

Abstract

Rasagiline ((R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; CAS 136236-51-6; molecular formula C12H13N; molecular weight 171.24) is a second-generation irreversible MAO-B inhibitor developed at Teva and approved by the FDA in 2006 under the trade name Azilect. Structurally distinct from selegiline by the indane scaffold replacing the phenethylamine, rasagiline does not yield amphetamine-class metabolites, simplifying its drug screening profile and avoiding the subjective stimulation associated with selegiline. MAO-B selectivity is approximately 14:1 over MAO-A at clinical dose (1 mg daily); the inhibition is irreversible and recovery requires de novo enzyme synthesis (approximately 14-day washout). Approved as monotherapy in early Parkinson disease and as adjunct to levodopa in advanced disease. The ADAGIO trial suggested possible disease-modifying effect for the 1 mg dose, though this remains debated. Tyramine restriction is not required at 1 mg daily; at higher experimental doses (2 mg) the cheese-effect risk emerges. Plasma half-life is approximately 3 hours, but the irreversible binding produces effective enzyme inhibition for weeks. Used as a reference second-generation MAO-B inhibitor in Parkinson research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-225Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 58 59 60 61 62 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.